Grifols SA (GRFS)
9.47
-0.08
(-0.84%)
USD |
NASDAQ |
Nov 15, 16:00
9.475
0.00 (0.00%)
After-Hours: 20:00
Grifols Research and Development Expense (TTM): 412.09M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 412.09M |
| June 30, 2024 | 412.05M |
| December 31, 2023 | 423.03M |
| September 30, 2023 | 395.01M |
| June 30, 2023 | 390.22M |
| December 31, 2022 | 398.14M |
| September 30, 2022 | 376.04M |
| June 30, 2022 | 378.01M |
| June 30, 2021 | 370.78M |
| March 31, 2021 | 348.02M |
| December 31, 2020 | 336.38M |
| September 30, 2020 | 323.18M |
| June 30, 2020 | 315.82M |
| March 31, 2020 | 312.64M |
| December 31, 2019 | 308.87M |
| September 30, 2019 | 305.86M |
| June 30, 2019 | 297.50M |
| March 31, 2019 | 288.49M |
| December 31, 2018 | 283.67M |
| September 30, 2018 | 328.94M |
| June 30, 2018 | 332.12M |
| March 31, 2018 | 331.20M |
| December 31, 2017 | 327.93M |
| September 30, 2017 | 254.33M |
| Date | Value |
|---|---|
| June 30, 2017 | 241.82M |
| March 31, 2017 | 229.29M |
| December 31, 2016 | 218.84M |
| September 30, 2016 | 239.38M |
| June 30, 2016 | 241.22M |
| March 31, 2016 | 243.68M |
| December 31, 2015 | 248.55M |
| September 30, 2015 | 242.73M |
| June 30, 2015 | 238.62M |
| March 31, 2015 | 244.90M |
| December 31, 2014 | 239.37M |
| September 30, 2014 | 217.85M |
| June 30, 2014 | 203.86M |
| March 31, 2014 | 177.08M |
| December 31, 2013 | 163.86M |
| September 30, 2013 | 163.12M |
| June 30, 2013 | 160.57M |
| March 31, 2013 | 161.47M |
| December 31, 2012 | 159.93M |
| September 30, 2012 | 157.46M |
| June 30, 2012 | 157.76M |
| March 31, 2012 | 145.68M |
| December 31, 2011 | 124.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
308.87M
Minimum
Dec 2019
423.03M
Maximum
Dec 2023
366.69M
Average
376.04M
Median
Sep 2022
Research and Development Expense (TTM) Benchmarks
| DBV Technologies SA | 83.21M |
| Cellectis SA | 94.63M |
| Akari Therapeutics PLC | 8.848M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 35.08M |